Report cover image

DNA topoisomerase I inhibitors - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 80 Pages
SKU # DEL19993762

Description

DelveInsight’s, “DNA topoisomerase I inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase I inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
DNA topoisomerase I inhibitors Understanding

DNA topoisomerase I inhibitors: Overview

DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase I inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase I inhibitors.
DNA topoisomerase I inhibitors Emerging Drugs Chapters

This segment of the DNA topoisomerase I inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DNA topoisomerase I inhibitors Emerging Drugs
  • Sacituzumab govitecan: Immunomedics
Sacituzumab govitecan is an antibody–drug conjugate composed of an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody coupled to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor through a proprietary hydrolyzable linker. Currently, it is in Phase III stage of development to treat Solid tumours.
  • Trastuzumab Deruxtecan: Daiichi Sankyo
Trastuzumab deruxtecan is a HER2 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Trastuzumab deruxtecan (5.4 mg/kg) is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Trastuzumab deruxtecan (6.4 mg/kg) is also approved in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer.

Further product details are provided in the report……..

DNA topoisomerase I inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different DNA topoisomerase I inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on DNA topoisomerase I inhibitors
There are approx. 20+ key companies which are developing the DNA topoisomerase I inhibitors. The companies which have their DNA topoisomerase I inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Immunomedics.
  • Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
DNA topoisomerase I inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DNA topoisomerase I inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA topoisomerase I inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase I inhibitors drugs.

DNA topoisomerase I inhibitors Report Insights
  • DNA topoisomerase I inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
DNA topoisomerase I inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing DNA topoisomerase I inhibitors drugs?
  • How many DNA topoisomerase I inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of DNA topoisomerase I inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase I inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for DNA topoisomerase I inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Immunomedics
  • Daiichi Sankyo
  • Ipsen
  • Luye Pharma Group
  • Hanmi Pharmaceutical
  • Biocompatibles International
  • Valent Technologies
  • Elucida Oncology
  • Cybrexa Therapeutics
  • Linus Oncology
  • Lee's Pharmaceutical
  • SN BioScience
  • Cebiotex
Key Products
  • Sacituzumab govitecan
  • Trastuzumab deruxtecan
  • Irinotecan sucrosofate
  • DS-1062
  • LY 01610
  • Irinotecan/encequidar
  • CM-BC2
  • VAL-413
  • DS 6000
  • CEB-01
  • SN 38
  • ELU 001
  • Gimatecan
  • LMP 744
  • CBX-12


Please Note: It will take 3-4 business days to complete the report upon order confirmation.

Table of Contents

80 Pages
Introduction
Executive Summary
DNA topoisomerase I inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA topoisomerase I inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sacituzumab govitecan: Immunomedics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Irinotecan hydrochloride liposomal: Luye Pharma Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Irinotecan: Valent Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA topoisomerase I inhibitors Key Companies
DNA topoisomerase I inhibitors Key Products
DNA topoisomerase I inhibitors- Unmet Needs
DNA topoisomerase I inhibitors- Market Drivers and Barriers
DNA topoisomerase I inhibitors- Future Perspectives and Conclusion
DNA topoisomerase I inhibitors Analyst Views
DNA topoisomerase I inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us